Indantadol (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Indantadol" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

9nih.gov

4^th place

3^rd place

7doi.org

2^nd place

3elsevier.com

610^th place

525^th place

2web.archive.org

1^st place

2vernalis.com

low place

1jcheminf.com

low place

33^rd place

1wikipedia.org

low place

1wkhealth.com

low place

2,251^st place

1aspetjournals.org

6,663^rd place

1,410^th place

1archive.org

6^th place

5^th place

archive.org

Barbieri M, Bregola G, Buzzi A, et al. (August 2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333–41. DOI:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

aspetjournals.org

jpet.aspetjournals.org

Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14. DOI:10.1124/jpet.103.050039. PMID 12750440.

doi.org

dx.doi.org

Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
Villetti G, Bregola G, Bassani F, et al. (June 2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866–78. DOI:10.1016/S0028-3908(01)00026-0. PMID 11378157.
Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157–66. DOI:10.1016/S0091-3057(01)00591-3. PMID 11566153.
Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071–4. DOI:10.1097/00001756-200211150-00016. PMID 12438928.
Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14. DOI:10.1124/jpet.103.050039. PMID 12750440.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565–74. DOI:10.1016/j.jpain.2006.02.004. PMID 16885013.
Barbieri M, Bregola G, Buzzi A, et al. (August 2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333–41. DOI:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

elsevier.com

linkinghub.elsevier.com

Villetti G, Bregola G, Bassani F, et al. (June 2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866–78. DOI:10.1016/S0028-3908(01)00026-0. PMID 11378157.
Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157–66. DOI:10.1016/S0091-3057(01)00591-3. PMID 11566153.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565–74. DOI:10.1016/j.jpain.2006.02.004. PMID 16885013.

jcheminf.com

Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

nih.gov

ncbi.nlm.nih.gov

Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
Villetti G, Bregola G, Bassani F, et al. (June 2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866–78. DOI:10.1016/S0028-3908(01)00026-0. PMID 11378157.
Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157–66. DOI:10.1016/S0091-3057(01)00591-3. PMID 11566153.
Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071–4. DOI:10.1097/00001756-200211150-00016. PMID 12438928.
Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14. DOI:10.1124/jpet.103.050039. PMID 12750440.
„CHF 3381”. Drugs in R&D 5 (1): 28–30. 2004. PMID 14725488.
Mattia C, Coluzzi F (September 2007). „Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain”. IDrugs : the Investigational Drugs Journal 10 (9): 636–44. PMID 17786847.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565–74. DOI:10.1016/j.jpain.2006.02.004. PMID 16885013.
Barbieri M, Bregola G, Buzzi A, et al. (August 2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333–41. DOI:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

vernalis.com

„IN-STEP Phase IIb study results”. Arhivirano iz originala na datum 2014-08-13.
„Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. Arhivirano iz originala na datum 2014-08-13.

web.archive.org

„IN-STEP Phase IIb study results”. Arhivirano iz originala na datum 2014-08-13.
„Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. Arhivirano iz originala na datum 2014-08-13.

wikipedia.org

sh.wikipedia.org

Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

wkhealth.com

meta.wkhealth.com

Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071–4. DOI:10.1097/00001756-200211150-00016. PMID 12438928.